Works by Haggag, Amina Z.

Results: 3

Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist.
Published in:
Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 551, doi. 10.1111/dom.16047
By:
- Haggag, Amina Z.;
- Xu, Jianfeng;
- Butcher, Laurie;
- Pagnussat, Sandra;
- Davies, Graeme;
- Lundqvist, Sara;
- Wang, Wenyu;
- Van Zuydam, Natalie;
- Nelander, Karin;
- Jha, Aruni;
- Yu, Hongtao;
- Boianelli, Alessandro;
- Lindmark, Bosse;
- Ollerstam, Anna;
- Sun, Xuefeng;
- Wang, Fan;
- Pan, Xiaoliang;
- Liu, Haihui;
- Chen, Wengang;
- Wallenius, Kristina
Publication type:
Article
Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study.
Published in:
Diabetes, Obesity & Metabolism, 2025, v. 27, n. 1, p. 215, doi. 10.1111/dom.16005
By:
- Amin, Neeta B.;
- Frederich, Robert;
- Tsamandouras, Nikolaos;
- Haggag, Amina Z.;
- Schuster, Tilman;
- Zmuda, Witold;
- Palmer, Alexandra;
- Vasas, Szilard;
- Buckley, Gina;
- Smith, Timothy R.;
- DuBrava, Sarah J.;
- Zhu, Qi;
- Johnson, Margot
Publication type:
Article
Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers.
Published in:
Clinical Pharmacokinetics, 2024, v. 63, n. 1, p. 57, doi. 10.1007/s40262-023-01319-2
By:
- Nader, Ahmed;
- Alexander, Elizabeth;
- Brintziki, Dimitra;
- Haggag, Amina Z.;
- Harrison, Stephen A.;
- Hawes, Ian A.;
- Hezareh, Marjan;
- Lippa, Andrew M.;
- Okamasa, Arisa;
- Okour, Malek;
- Okuda, Nobuhiko;
- Sager, Jennifer E.;
- Segal, Scott;
- Shida, Yuri;
- Skingsley, Andrew;
- Williams, Robert;
- Yoon, Esther Y.;
- Austin, Daren
Publication type:
Article

Works by Haggag, Amina Z.

Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist.

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study.

Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers.